Anasuya Gunturi
Internal Medicine · Boston, MANPI 1760619183
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (53.4%), consulting fees and education — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by AstraZeneca at 47.2% of the total. Reporting peaked in 2024 at $622 and has fallen 88.4% since, to $72 in 2025.
Across 27 payments — averaging $42.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$543
- E.r. Squibb & Sons, L.L.C.$181
- Daiichi Sankyo Inc.$68
- Johnson & Johnson$66
- Genentech USA, Inc.$49
- GSK$43
- plus $200 from 10 others
Across 24 payments — averaging $1678.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$23K
- Merck$17K
What the payments were for
- Consulting fees$52546%
- Food & beverage$61453%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 2 | $543 |
| E.r. Squibb & Sons, L.L.C. | 7 | $181 |
| Daiichi Sankyo Inc. | 2 | $68 |
| Johnson & Johnson | 3 | $66 |
| Genentech USA, Inc. | 2 | $49 |
| GSK | 1 | $43 |
| Pfizer | 1 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $28 |
| Eisai Inc. | 1 | $25 |
| Seagen Inc. | 1 | $22 |
| Foundation Medicine, Inc. | 1 | $20 |
| Puma Biotechnology, Inc. | 1 | $20 |
| Novartis | 1 | $18 |
| Amgen | 1 | $14 |
| Incyte Corporation | 1 | $12 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYNPARZA$525
How this compares
$1,151 in reported general payments places this provider in the 85th percentile of 4,983 internal medicine providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abiraterone Acetate | 16 | $18,902 |
| Anastrozole | 215 | $4,538 |
| Dexamethasone | 88 | $1,266 |
| Prochlorperazine Maleate | 114 | $1,057 |
| LoperamideLoperamide Hcl | 45 | $416 |
| Lorazepam | 67 | $158 |
| Prednisone | 23 | $116 |
| Acyclovir | 11 | $108 |
| Trazodone Hcl | 11 | $44 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Boston
- David SchenkeinBoston$5M
- John FallonBoston$1.8M
- Michael MendelsohnBoston$1.6M
- Gaurav SingalBoston$798K
- Asit ParikhBoston$486K
- Noopur RajeBoston$481K
- Daniel KuritzkesBoston$443K
- Xiuning leBoston$364K
- Nancy GaglianoBoston$358K
- Fatima StanfordBoston$285K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.